Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2025 04:23 ET | Source: Research and Markets

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibodies Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The global bispecific...
September 30, 2025 10:00 ET | Source: Precedence Research

Next-Generation Bispecific Antibody Market Trends and Competitive Landscape Report

Ottawa, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The next-generation bispecific antibody market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue...
August 26, 2025 04:11 ET | Source: Research and Markets

Bispecific Antibody Drug Conjugates Clinical Trials and Competitive Landscape Report 2025 | Over 100 Bispecific ADCs Progressing in Clinical Trials

Dublin, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape & Market Opportunity Insight 2025" report has...
August 08, 2025 06:30 ET | Source: SNS Insider pvt ltd

Multiple Myeloma Market Size to Reach USD 46.94 Billion by 2032 | Immunotherapy, CAR-T, and Precision Medicine Lead Growth – SNS Insider

Austin, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Multiple Myeloma Market Size & Growth Analysis According to SNS Insider, the global Multiple Myeloma Market was valued at USD 26.83 billion in 2024 and...
July 29, 2025 11:03 ET | Source: Research and Markets

Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More

Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibodies Market Industry Trends and Global Forecasts to 2035: By Therapeutic Area, Mechanism of Action, Target Antigen, Antibody Format,...
July 07, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

New York, USA, July 07, 2025 (GLOBE NEWSWIRE) -- Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The...
June 02, 2025 06:45 ET | Source: BioNTech SE

BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt

BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen...
June 02, 2025 06:45 ET | Source: BioNTech SE

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new...
April 23, 2025 04:04 ET | Source: Research and Markets

Prostate-Specific Membrane Antigen (PSMA) Targeted Therapy Pipeline Review 2025 Tracks Drug Candidates for Prostate Cancer

Dublin, April 23, 2025 (GLOBE NEWSWIRE) -- The "PSMA - Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This report provides information on approved...
March 31, 2025 20:00 ET | Source: Shanghai EpimAb Biotherapeutics Co., Ltd.

EpimAb Biotherapeutics Announces Four Upcoming Presentations at the 2025 American Association for Cancer Research Annual Meeting

SHANGHAI, April 01, 2025 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased...